Diagnos Inc. announced the signing of an agreement with Novartis Pharma AG, for the continuation and expansion of joint deployment and usage of CARA in the United Arab Emirates. Novartis' team in the United Arab Emirates view CARA screening platform as an excellent tool within the context of their activities. With Diagnos Inc.'s assistance, they hope to slow or reverse vision impairment caused by a high prevalence of diabetes within a large patient population.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
0.32 CAD | +3.23% |
|
+6.67% | -20.99% |
06-05 | DIAGNOS Raises $0.98 Million in the Second and Final Tranche of a Private Placement of Share Units | MT |
06-05 | DIAGNOS Inc. announced that it has received CAD 1.295821 million in funding | CI |
![Consensus](/images/consensus_flch.gif)
1st Jan change | Capi. | |
---|---|---|
-20.99% | 18.48M | |
-7.38% | 199B | |
+10.15% | 181B | |
+13.61% | 168B | |
+5.52% | 99.31B | |
+44.54% | 91.84B | |
+14.08% | 85.57B | |
+11.87% | 84.59B | |
+7.06% | 50.83B | |
-31.55% | 44.78B |
- Stock Market
- Equities
- ADK Stock
- News DIAGNOS Inc.
- Diagnos Inc. Announces Signing of an Agreement with Novartis Pharma AG